4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-26-154908
Chief Development Officer sold 19,865 shares at an average $35.03 ($695,823)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Yeleswaram Krishnaswamy · Chief Development Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-04-10 | Sale : show line 1 in the form 10b5-1 | −500 | $34.98 | $17,490 | 286,016 | D |
| 2026-04-13 | Sale : show line 2 in the form 10b5-1 | −9,165 | $34.97 | $320,537 | 276,851 | D |
| 2026-04-14 | Sale : show line 3 in the form 10b5-1 | −10,200 | $35.08 | $357,797 | 266,651 | D |
| Open-market sales · 19,865 sh · avg $35.03 · $695,823 | ||||||
Loading xslF345X06/ownership.xml…